Trametinib is an NF1 inhibitor which is also known as a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor with anticancer activity and is FDA approved for use in metastatic malignant melanoma (76). The gene discussed is MAP2K7; the disease is metastatic melanoma.